We assayed [9,10(n)-3Hlpalmitate oxidation by fibroblast monolayers from patients with fatty acid oxidation disorders. Activities in the different disorders were (percent control): short-chain acylcoenzyme A (CoA) dehydrogenase deficiency (115%), medium chain acyl-CoA dehydrogenase deficiency (18%), long-chain acyl-CoA dehydrogenase deficiency (28%), multiple acyl-CoA dehydrogenation disorder, mild and severe variants (49% and 7%), and palmityl-carnitine transferase deficiency (4%). Multiple acyl-CoA dehydrogenation disorder, medium chain acyl-CoA dehydrogenase-deficient lines, and long-chain acyl-CoA dehydrogenase-deficient lines all complemented one another after polyethylene glycol fusion, with average activity increases of 31-83%. We detected two complementation groups in the severe multiple acyl-CoA dehydrogenation disorder lines, consistent with deficiencies of either electron transfer flavoprotein or electron transfer flavoprotein:ubiquinone oxidoreductase. The metabolic block in the latter cell lines is threefold more severe than in the former (P < 0.001). No intragenic complementation was observed within either group. We assigned two patients with previously unreported severe multiple acyl-CoA dehydrogenation disorder to the electron transfer flavoprotein:ubiquinone oxidoreductase-deficient group.
1. Abbreviations used in this paper: ADH, acyl-coenzyme A dehydrogenase; CoA, coenzyme A; ETF, electron transfer flavoprotein; ETF: QO, electron transfer flavoprotein:coenzyme Q oxidoreductase; LCD, long-chain acyl-coenzyme A dehydrogenase deficiency; MAD, multiple acyl-coenzyme A dehydrogenation disorder; MAD:M, multiple acylcoenzyme A dehydrogenation disorder, mild variant; MAD:S, multiple acyl-coenzyme A dehydrogenation disorder, severe variant; MCD, medium-chain acyl-coenzyme A dehydrogenase deficiency; MEM/10, Ea- gle's minimum essential medium with 10% fetal calf serum, 2 mM glutamine, 140 AM penicillin, 88 MM streptomycin; PCT, palmityl-carnitine transferase deficiency; PEG, polyethylene glycol; SCD, short-chain acylcoenzyme A dehydrogenase deficiency. excreting ethylmalonate and methylsuccinate (1, 2) . MCD is characterized by episodic hypoketotic hypoglycemia and a medium-chain dicarboxylic aciduria, whereas LCD can also produce hypotonia and hypertrophic cardiomyopathy (3) (4) (5) . The MAD are characterized biochemically by the inability of affected individuals to metabolize all the acyl-CoAs normally oxidized via the acyl-CoA dehydrogenases (6-9), whereas PCT-deficient patients have an isolated defect in long-chain fatty acid oxidation (10) .
Clinical symptoms of the MAD include varied degrees of hypoketotic hypoglycemia, acidosis, fatty changes in liver, kidney, and sometimes heart, and accumulation and excretion of dethiolated acyl-CoAs and their derived oxidation products (8) . Goodman and Frerman (8) have designated three clinical subgroups ofMAD: neonatal onset MAD with congenital defects, neonatal onset MAD without congenital defects, and late onset MAD. The first two groups constitute the disorder's severe forms, MAD:S or glutaric aciduria type II. Fibroblasts from MAD:S patients oxidize radiolabeled fatty acids, leucine, and lysine very poorly (6) (7) (8) (9) . The MM [3H]palmitate and 0.5 mg/ml BSA with HBSS. 0.2 ml of this mixture was applied to wells containing unfused and fused monolayers rinsed twice with 1.5 ml of Dulbecco's PBS. Blanks were prepared by applying 0.1 ml methanol to both unfused and fused monolayers for 30 s. Additional PEG-treated wells were also methanol killed and stained with Giemsa (I1/10 in Dulbecco's PBS) for 2 min to determine the proportion of fused cells. All monolayers were inspected before the application of reaction mixture, and only those monolayers with >40% multinucleate cells in good condition were used.
Cells were incubated in the above reaction mixture for 2 h at 370 in humidified 5% C02/95% air. After incubation, the reaction mixture was removed and added to a centrifuge tube containing 0.2 ml of 10% (wt/ vol) trichloroacetic acid. Each well was rinsed with 0.1 ml of Dulbecco's PBS, which was added to the tube. After 2 min at room temperature, the reaction mixture was centrifuged at 8,500 g in a Beckman microfuge for 5 min. Supernatants were immediately removed, then 0.07 ml of 6 N NaOH was added and applied to a 1-ml Dowex-I column in a pasteur pipette. Columns were rinsed with I ml of distilled water, and the eluate was collected in a scintillation vial containing 10 ml of Scintiverse I (Fisher Scientific Co., Pittsburg, PA). The samples were then counted. The monolayer was rinsed twice in 1.5 ml Dulbecco's PBS, sonicated 
Discussion
The fatty acid oxidation disorders are a group of diseases involving defects in (3-oxidation and acyl-CoA metabolism. Assays for detection and characterization of the biochemical defects in these disorders are essential tools for clinical diagnosis and research. We have developed a sensitive, reliable, and rapid assay for disorders affecting #-oxidation of long-chain fatty acids, i.e.,
palmitate. Other intact cell screening assays for these disorders 25) . We have confirmed our assignment of ETF deficiency to MAD:S line 1401 by direct enzyme assay (13). As those ETFdeficient immunochemically studied MAD:S lines (1400, 1430, 1441) have had abnormal a-ETF subunits (25), our results suggest that cell line 1401 also has an a-ETF abnormality. Our assay system should also detect another MAD:S complementation group corresponding to defects in the flSsubunit of ETF, although no such cases have yet been identified. We found no intragenic complementation within the ETF-and ETF:QO-deficient MAD:S groups. While MAD:M lines also complement MCD and LCD cell lines, we have not yet assigned new MAD: M lines to the ETF-or ETF:QO-deficient groups. This approach should prove quite feasible. We also find the metabolic block in the ETF:QO-deficient MAD:S lines is threefold more severe than in ETF-deficient lines (P < 0.001). Since MAD:S patients with ETF:QO deficiency have distinctive congenital malformations, whereas those with ETF deficiency do not (8, 13, 14) , the severity ofthe metabolic block, rather than its location, and the resulting profound acidosis in utero may have disturbed normal morphogenesis.
